Stockscreener 앱 받기
29.44
2.15%
0.62
시간 외 거래:
29.44
전일 마감가:
$28.82
열려 있는:
$29.98
하루 거래량:
547.17K
Relative Volume:
0.99
시가총액:
$1.81B
수익:
-
순이익/손실:
$-209.84M
주가수익비율:
-6.442
EPS:
-4.57
순현금흐름:
$-6.73M
1주 성능:
-10.76%
1개월 성능:
+16.09%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$29.02
$30.90
1주일 범위
$28.25
$34.74
52주 변동 폭
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
명칭
Damora Therapeutics Inc
전화
(781) 281-9020
주소
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
29.44 | 1.77B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | RBC Capital Mkts | Outperform |
| 2026-03-25 | 개시 | Evercore ISI | Outperform |
| 2026-02-17 | 개시 | UBS | Buy |
| 2026-01-07 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Guggenheim | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | BofA Securities | Buy |
| 2020-11-23 | 개시 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | SVB Leerink | Outperform |
모두보기
Damora Therapeutics Inc 주식(DMRA)의 최신 뉴스
DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus
H.C. Wainwright reiterates Damora Therapeutics stock rating on device advantage - Investing.com Canada
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies initiates Damora Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Damora Therapeutics, Inc. Revenue Breakdown – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics (DMRA) AGM 2026 Summary - Quartr
Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
symbol__ Stock Quote Price and Forecast - CNN
DMRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
H.C. Wainwright reiterates Buy on Damora Therapeutics stock By Investing.com - Investing.com Canada
Damora Therapeutics Completes Cayman Islands Redomestication - TipRanks
Damora Therapeutics completes redomestication to Cayman Islands - Investing.com
Damora Announces Redomestication from Delaware to Cayman Islands - The Manila Times
Damora Will Keep DMRA Ticker Under New Nasdaq CUSIP July 20 - Stock Titan
Damora Therapeutics Inc. (DMRA) Q1 2026 Earnings: Wider-than-Expected Loss on Pre-Revenue Pipeline Progress - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Damora Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerGeographic Revenue Trends - dars.gov.et
Is Broad Russell Index Inclusion Altering The Investment Case For Damora Therapeutics (DMRA)? - simplywall.st
Damora Therapeutics (DMRA) Sheds Over 6%: Support Levels in Focus After Sharp DeclineDealer Delta - dars.gov.et
Form 4 Damora Therapeutics Inc For: 7 July By Investing.com - Investing.com South Africa
Damora Therapeutics general counsel sells $7,345 in stock By Investing.com - Investing.com Nigeria
Damora Therapeutics general counsel sells $7,345 in stock - Investing.com
[Form 4] Damora Therapeutics, Inc. Insider Trading Activity - Stock Titan
Price to earnings forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Price to sales forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Damora awards 453,500 stock options to nine new hires - Stock Titan
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Index - marketscreener.com
Damora Therapeutics (DMRA) Is Up 6.2% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Damora Therapeutics, Inc. Actuals & Estimates (NASDAQ:DMRA) - TradingView
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Value Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Damora Therapeutics (DMRA) Slides 4.5%: Key Support Levels in FocusGamma Flip Level - DonanımHaber
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000 Value Benchmark - marketscreener.com
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts - Quiver Quantitative
Damora Therapeutics Inc (DMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):